STOCK TITAN

RHYTHM PHARMACEUTICALS (RYTM) SEC Filings, Jul 9-11, 2025

RYTM NASDAQ

Rhythm Pharmaceuticals, Inc.'s SEC filings document a commercial-stage biopharmaceutical company whose disclosures center on IMCIVREE (setmelanotide), MC4R pathway rare-disease indications and related clinical and regulatory milestones. Recent Form 8-K reports include operating results, product-revenue commentary, FDA and European regulatory updates for acquired hypothalamic obesity, and trial disclosures for programs such as TRANSCEND and EMANATE.

Rhythm's proxy materials and governance filings disclose board composition, director elections, executive compensation, equity awards and shareholder voting matters. Other current reports record director changes, Regulation FD materials, presentations and press releases, tying corporate governance and public-company reporting to the company's rare neuroendocrine disease portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
insider
Rhea-AI Summary

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) filed an 8-K announcing that on July 9, 2025 it entered into an underwriting agreement with Morgan Stanley & Co. LLC and BofA Securities, Inc. to issue 2,058,824 common shares at $85.00 per share. The underwriters fully exercised their 30-day option for an additional 308,823 shares, bringing the total to 2,367,647 shares. Closing is expected on July 11, 2025, subject to customary conditions.

Gross proceeds are about $201.3 million; net proceeds, after underwriting discounts and estimated expenses, are expected to be $188.7 million. The transaction was conducted under the company’s effective Form S-3 shelf registration (File No. 333-270233) and is supported by a legal opinion from Latham & Watkins LLP.

Management plans to deploy the funds to:

  • Advance clinical development of pipeline product candidates
  • Support commercialization of IMCIVREE
  • Provide working capital and cover general corporate purposes

Based on current operating plans, Rhythm believes its existing cash, cash equivalents, short-term investments, and the net proceeds from this offering will fund operations for at least the next 24 months. Forward-looking statements in the filing note that actual cash needs could differ due to market or operational factors.

Key exhibits include the Underwriting Agreement (Ex. 1.1) and related legal opinion (Ex. 5.1).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
prospectus
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
prospectus
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
current report
-
Form 144
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
other
-
Form 144
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
other
Form 144
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
other

FAQ

How many RHYTHM PHARMACEUTICALS (RYTM) SEC filings are available on StockTitan?

StockTitan tracks 138 SEC filings for RHYTHM PHARMACEUTICALS (RYTM), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for RHYTHM PHARMACEUTICALS (RYTM)?

The most recent SEC filing for RHYTHM PHARMACEUTICALS (RYTM) was filed on November 17, 2026.